Vyvanse Q1 velocity signals blockbuster and beyond for Shire
This article was originally published in Scrip
Executive Summary
Strong Q1 sales figures and significant velocity for its ADHD product Vyvanse suggest that Shire Pharmaceuticals will be heralding a new blockbuster by the end of the year. Furthermore, with approval pending in European markets and investigations into additional psychiatric indications providing promising results, Vyvanse is set to deliver long-term sales growth.